Health Condition 1: B377- Candidal sepsis Health Condition 2: B440- Invasive pulmonary aspergillosis Health Condition 3: B460- Pulmonary mucormycosis Health Condition 4: A403- Sepsis due to Streptococcus pneumoniae Health Condition 5: A410- Sepsis due to Staphylococcus aureus Health Condition 6: A413- Sepsis due to Hemophilus influenzae Health Condition 7: A415- Sepsis due to other Gram-negativeorganisms Health Condition 8: A419- Sepsis, unspecified organism
Conditions
Interventions
Intervention1: enteral melatonin in critically ill patients: 20mg of melatonin in form of 4 doses of 5mg tablets given every 1hourly starting from 9pm through ryles tube
Control Intervention1: placeb
Sponsors
Addetlla Sravani
Eligibility
Inclusion criteria
Inclusion criteria: 1. patients admitted to ICU within 2 days of hospital admission 2.patients with suspected risk of infections 3.patients with anticipated ICU stay of more than 5 days
Exclusion criteria
Exclusion criteria: 1.Patients known to be pregnant 2.Patients having allergy to study drug 3.receiving palliative care or not expected to survive more than 12 hrs 4.patients receiving any anticoagulant therapy 5.known to have received another interventional trial that might interact with study drug
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Incidence of invasive fungal infections 2.Susceptibility profile in form of MIC values of antifungal agents Timepoint: Day 1 of ICU admission Day 5 Day 7 Day 10 Day 14 Day 28 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.total days of free antifungal therapy 2.Incidence of bacterial sepsis and septic shock 3.susceptibility profile of bacterial agents 4.ventilator free days 5.length of ICU stay 6.Outcome (sepsis and septic shock, deathTimepoint: throughout the 28days of ICU stay or till death, which ever is earlier | — |
Countries
India
Contacts
Public ContactDrMunesh kumar Gupta
Institute of medical sciences, Banaras Hindu University
Outcome results
None listed